Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-02-05

FDA Approved: BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE — Supplemental Application (Viona Pharmaceuticals Inc)

View source ↗

Summary

FDA approved a supplemental application for Bisoprolol Fumarate and Hydrochlorothiazide from Viona Pharmaceuticals, enabling a new generic combination product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Bisoprolol Fumarate and Hydrochlorothiazide (bisoprolol fumarate and hydrochlorothiazide)

Snippet

SUPPL AP for BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE (BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE)